Ortek Therapeutics
This article was originally published in The Tan Sheet
Executive Summary
Garden City, N.Y. firm to begin a U.S. trial by year end examining the effects of Cavistat on xerostomia (dry mouth) induced caries. Cavistat, which Ortek licenses from the State University of New York at Stonybrook, is a patented combination of arginine, calcium and a "cariostatic anion" thought to remineralize teeth. Ortek may launch a dentifrice containing the ingredient next year; the firm also is exploring marketing partnerships with larger companies. A 12-week, 100-subject trial already has been conducted showing Cavistat to be effective in treating tooth sensitivity, and another 750-subject caries study taking place in South America is scheduled to be completed in roughly a year
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning